How CVS Deal Renewal At Cardinal Health Stock Has Changed Its Investment Story

• On 1 October 2026, Cardinal Health disclosed a binding Letter of Intent to extend its distribution agreement with CVS Health through 30 June 2032, maintaining the current scope of services.
• This renewal signals that a core customer intends to keep relying on Cardinal Health's existing distribution footprint. This can influence volume visibility, capacity planning and contract negotiations with manufacturers across its broader network.
• We will now look at how Cardinal Health's extended CVS distribution agreement reshapes the broader investment narrative around its distribution platform.

Seize this chance to compare Cardinal Health's renewed distribution stability with a curated list of solid balance sheet and fundamentals (25 results) that could handle similar long-term customer commitments.

Cardinal Health Investment Narrative Recap

To own Cardinal Health, you need to believe that a huge, low margin distribution engine can steadily lean into higher value services without losing key customers. The CVS extension supports that belief by locking in a major client through 2032, which can help near term volume visibility and planning, but probably does not transform the short term earnings story on its own.

The more immediate swing factors still sit in execution. Investors are watching whether higher margin units such as specialty distribution, Biopharma Solutions and at Home Solutions keep scaling cleanly, while product quality issues and input cost pressure in Global Medical Products and Distribution remain contained so that recent profit repairs do not come under renewed strain.

The nationwide Class II recalls of subpotent levothyroxine tablet lots linked to Cardinal Health sit uncomfortably next to this fresh proof of customer stickiness with CVS. One development speaks to commercial durability. The other speaks to operational oversight. Together they frame the near term question for you as an owner around resilience of trust across manufacturers, regulators and pharmacy customers.

Recalls of this type can increase scrutiny of quality systems at the same time analysts are leaning on higher earnings contributions from specialty pharma services and the repaired medical segment. The CVS agreement may help underpin volume and network relevance, but the levothyroxine episode keeps the main risk acute, namely that any escalation in regulatory or reputational fallout would pressure margins just as higher value businesses are trying to do more of the heavy lifting.

Cardinal Health's current analyst narrative centers on revenues reaching US$297.6b and earnings of US$3.0b by 2029. That path assumes yearly revenue growth of 5.4%, with earnings increasing by US$1.3b from US$1.7b today.

Discover why Cardinal Health's fair value indicates a 14% potential upside to its current price that may not last much longer.

Exploring Other Perspectives

Fair value estimates for Cardinal Health from the Simply Wall St Community span roughly US$271 to about US$742 per share across 2 individual analyses, so you are looking at very different expectations sitting side by side. When you also consider the levothyroxine recall risk, the debate widens around how operational control could affect future performance. Use that spread as a prompt to explore several alternative viewpoints before anchoring on your own number.

Explore another Cardinal Health fair value estimate, including one that suggests it could be worth just $270.94.

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment outcomes rarely come from following the herd, so consider relying on your own judgment.

• A great starting point for your Cardinal Health research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• See our latest analysis for Cardinal Health. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Cardinal Health's overall financial health at a glance.

Looking for more investment ideas beyond Cardinal Health?

Once you have a view on Cardinal Health, it can help to line it up against other businesses that fit clear, rules-based criteria. The Simply Wall St Screener lets you do that quickly so you can see how this stock compares across quality, value and balance sheet strength.

• If you want companies that combine healthy balance sheets with solid fundamentals, start with a curated list of solid balance sheet and fundamentals (25 results) that can support long-term customer commitments similar to the CVS arrangement.
• If value is your focus and you prefer quality businesses trading at what may be undemanding prices, scan through a targeted 28 high quality undervalued stocks that apply both cash flow and balance sheet filters.
• If resilience matters most and you would rather sleep well at night, sort through a group of 31 resilient stocks with low risk scores that screen well on Simply Wall St's risk scoring.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com